SEC Comment Letter 0000000000-23-000926 to Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

Shuttle Pharmaceuticals Holdings, Inc.
Date: Jan. 27, 2023 · CIK: 0001757499 · Accession: 0000000000-23-000926

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-269414

Date

January 27, 2023

Author

Anatoly Dritschilo, M.D.

Form

UPLOAD

Company

Shuttle Pharmaceuticals Holdings, Inc.

Letter

United States securities and exchange commission logo January 27, 2023 Anatoly Dritschilo, M.D. Chief Executive Officer Shuttle Pharmaceuticals Holdings, Inc. One Research Court, Suite 450 Rockville, Maryland 20850 Re:Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1 Filed January 25, 2023 File No. 333-269414 Dear Anatoly Dritschilo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Megan J. Penick, Esq.

Show Raw Text

United States securities and exchange commission logo
January 27, 2023
Anatoly Dritschilo, M.D.
Chief Executive Officer
Shuttle Pharmaceuticals Holdings, Inc.
One Research Court, Suite 450
Rockville, Maryland 20850
Re:Shuttle Pharmaceuticals Holdings, Inc.
Registration Statement on Form S-1
Filed January 25, 2023
File No. 333-269414
Dear Anatoly Dritschilo:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Megan J. Penick, Esq.

SecProbe.io